Sarepta’s controversial Duchenne muscular dystrophy drug was contested right up to approval By: MarketWatch September 19, 2016 at 12:48 PM EDT One final twist was “highly unusual,” the FDA’s top leader said. Read More >> Related Stocks: Biomarin Pharmaceuticals Daiichi Sankyo Ltd Pfizer Sarepta Therapeutics Wave Life Sci Ord Sh